Overexpression of bax enhances antitumor activity of chemotherapeutic agents in human head and neck squamous cell carcinoma

Clinical Cancer Research

Volumn 6, Issue 2, 2000, Pages 718-724

  Guo, Bin ^a   Cao, Shousong ^a   Tóth, Károly ^a   Azrak, Rami G ^a   Rustum, Youcef M ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; IRINOTECAN; PROTEIN BAX; RALTITREXED;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CELL GROWTH; DRUG TOLERABILITY; FEMALE; HEAD CANCER; HUMAN; HUMAN CELL; MOUSE; NECK CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; XENOGRAFT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CAMPTOTHECIN; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; CELL SURVIVAL; DNA TOPOISOMERASES, TYPE I; ENZYME INHIBITORS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MICE; MICE, NUDE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; QUINAZOLINES; THIOPHENES; THYMIDYLATE SYNTHASE; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0033982752     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Reed, J. C. Bcl-2 family proteins. Oncogene, 17: 3225-3236, 1998.
2. Oltvai, Z. N., Milliman, C. L., and Korsmeyer, S. J. Bcl-2 heterodimerizes in vivo with a conserved homolog. Bax, that accelerates programmed cell death. Cell, 74: 609-619, 1993.
3. Miyashita, T., and Reed, J. C. bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res., 52: 5407-5411, 1992.
4. Walton, M. I., Whysong, D., O'Connor, P. M., Hockenbery, D., Korsmeyer, S. J., and Kohn, K. W. Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res., 53: 1853-1861, 1993.
5. Minn, A. J., Rudin, C. M., Boise, L. H., and Thompson, C. B. Expression of bcl-xL can confer a multidrug resistance phenotype. Blood, 86: 1903-1910, 1995.
6. Guo, B., Yin, M. B., Tóth, K., Cao, S., Azrak, R. G., and Rustum, Y. M. Dimerization of mitochondrial Bax is associated with increased drug response in Bax-transfected A253 cells. Oncol. Res., 11: 91-99, 1999.
7. Strobel, T., Swanson, L., Korsmeyer, S., and Cannistra, S. A. BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc. Natl. Acad. Sci. USA, 93: 14094-14099, 1996.
8. Kobayashi, T., Ruan, S., Clodi, K., Kliche, K. O., Shiku, H., Andreeff, M., and Zhang, W. Overexpression of Bax gene sensitizes K562 erythroleukemia cells to apoptosis induced by selective chemotherapeutic agents. Oncogene, 16: 1587-1591, 1998.
9. Touroutoglou, N., and Pazdur, R. Thymidylate synthase inhibitors. Clin. Cancer Res., 2: 227-243, 1996.
10. Rothenberg, M. L. Topoisomerase I inhibitors: review and update. Ann. Oncol., 8: 837-855, 1997.
11. Jackman, A. L., Taylor, G. A., Gibson, W., Kimbell, R., Brown, M., Calvert, A. H., Judson, I. R., and Hughes, L. R. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res., 51: 5579-5586, 1991.
12. Cao, S., McGuire, J. J., and Rustum, Y. M. Antitumor activity of ZD1694 (Tomudex) against human head and neck cancer in nude mice models: role of dosing schedule and plasma thymidine. Clin. Cancer Res., 5: 1925-1934, 1999.
13. Blackledge, G. New development in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed ('Tomudex'). Br. J. Cancer, 77 (Suppl 2): 29-37, 1998.
14. Cottu, P. H., Extra, J. M., Lerebours, F., Espie, M., and Marty, M. Clinical activity spectrum of Irinotecan. Bull. Cancer (Paris), 85: 21-25, 1998.
15. Yin, M. B., Tóth, K., Cao, S., Guo, B., Frank, C., Slocum, H. K., and Rustum, Y. M. Involvement of Cyclin D1-cdk5 overexpression and MCM3 cleavage in Bax-associated spontaneous apoptosis and differentiation in an A253 human head and neck carcinoma xenograft model. Int. J. Cancer, 83: 341-348, 1999.
16. Yin, M. B., Guo, B., Panadero, A., Frank, C., Wrzosek, C., Slocum, H. K., and Rustum, Y. M. Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor Tomudex. Exp. Cell Res., 247: 189-199, 1999.
17. Cao, S., Rustum, Y. M., and Spector, T. 5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res., 54: 1507-1510, 1994.